CALGARY, June 18, 2012 /PRNewswire/ – Dr. Brad Thompson, President and CEO of
Oncolytics Biotech Inc. (TSX: ONC, NASDAQ:ONCY), will present a
corporate overview of the Company at the Bloom Burton & Co. Healthcare
Investor Conference on June 21st, 2012 at 10:30 am ET. The Conference is being held at the Toronto Board
of Trade, 1 First Canadian Place, Toronto, Ontario on June 21st between 8:30 am and 4:30 pm ET.
The Bloom Burton & Co. Healthcare Investor Conference brings together
U.S., Canadian and European investors who are interested in the latest
developments in the Canadian healthcare sector. Attendees will have an
opportunity to obtain corporate updates from the premier Canadian
public and private companies through presentations and break-out Q&A
sessions.
About Bloom Burton & Co.
Bloom Burton & Co. is Canada’s largest and most active
healthcare-specialized investment banking group. The team of healthcare
specialists merges scientific, medical, clinical, intellectual property
and commercial expertise with a strong understanding of the capital
markets, to advise and raise capital for private and public companies.
For more information, please visit www.bloomburton.com.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the
development of oncolytic viruses as potential cancer therapeutics.
Oncolytics’ clinical program includes a variety of human trials
including a Phase III trial in head and neck cancers using REOLYSIN®, its proprietary formulation of the human reovirus. For further
information about Oncolytics, please visit: www.oncolyticsbiotech.com.
This release and the presentation related thereto contain
forward-looking statements which involve known and unknown risks,
delays, uncertainties and other factors not under the Company’s control
and which may cause actual results, performance or achievements of the
Company to be materially different from the results, performance or
expectations implied by these forward-looking statements. Such risks and uncertainties include, among others, the efficacy of
REOLYSIN as a cancer treatment, the success and timely completion of
clinical studies and trials, uncertainties related to the research and
development of pharmaceuticals and uncertainties related to the
regulatory process. Investors should consult the Company’s quarterly
and annual filings with the Canadian and U.S. securities commissions
for additional information on risks and uncertainties relating to the
forward-looking statements. Investors are cautioned against placing
undue reliance on forward-looking statements. The Company does not
undertake to update these forward-looking statements, except as
required by applicable laws.
SOURCE Oncolytics Biotech Inc.
Released June 18, 2012